Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs
- 1 August 2007
- journal article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 223 (1) , 39-45
- https://doi.org/10.1016/j.taap.2007.05.005
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Molecular clues into the pathogenesis of statin‐mediated muscle toxicityMuscle & Nerve, 2005
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- benefit-risk assessment of Rosuvastatin 10 to 40 milligramsThe American Journal of Cardiology, 2003
- Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemiaEuropean Journal of Pharmacology, 2003
- Gemfibrozil greatly increases plasma concentrations of cerivastatinClinical Pharmacology & Therapeutics, 2002
- Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case – a modern Pandora’s boxBiomedicine & Pharmacotherapy, 2002
- Guinea Pigs as Models for Cholesterol and Lipoprotein MetabolismJournal of Nutrition, 2001
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Inhibition of Cholesterol Synthesis by Squalene Synthase Inhibitors Does Not Induce Myotoxicityin VitroToxicology and Applied Pharmacology, 1997
- Cholesterol and mortality. 30 years of follow-up from the Framingham studyJAMA, 1987